It has become increasingly apparent that the treatment to eradicate the leukemia has adverse long-term side effects. These late side effects consist of organ toxicity, disturbances in growth, pubertal and fertility development, psychosocial problems, immunosuppression, and infections. Furthermore, children with cancer are at higher risk for the occurrence of second tumors.
Since 1972 virtually all newly diagnosed children with leukemia in The Netherlands are registered by the DCLSG. The DCLSG provides protocols for treatment and disposes of a Central Office for data management and analysis of treatment results and a Laboratory for confirmation of the diagnosis, immunophenotyping, and classification of the leukemia as well as for follow-up by examination of routine bone marrow and peripheral blood during treatment and after cessation of therapy.
Here we report the results of the DCLSG study on late events and long-term side effects in 392 survivors out of 1193 LATE EFFECfS AMONG LONG-TERM SURVIVORS OF ACUTE LEUKEM IA 803 consecutively newly diagnosed children with leukemia (age 0-15 y) in the period 1972-1982, treated with chem otherapy and radiotherapy (cranial irradiation).
METHODS

Patients.
Patients registered by the DCLSG at diagnosis and in first CCR for at least 6 y at January 1, 1988 , were eligible for the study.
Treatment. From 1972 From to 1975 all ALL patients were treated acco rding to the DCLSG protocols I and Il, respectively. After 1975 ALL patients were stratified into two risk groups: ALL-NHR constituting 70% of all ALL patients, and ALL-HR, 30% of the patients. ALL-NHR was defined as: initial WBC < 50 X 10 9/L , no mediastinal mass, no initial CNS involvement. All other patients were ALL-HR patients. Children with ALL -NHR were treated according to the DCLSG protocols AL L III and ALL Y, respectively, children with ALL-HR accordin g to institutional protocols.
Until 1980, children with ANL L were also treated according to institutional protocols, thereafter until 1982 according to the DCLSG protocol ANLL 80. The treatment schemes and results of these DCLSG protocols have been publis hed elsewhere (5) (6) (7) (8) (9) .
Late events. Registr ation forms with treatment documentation, data on remission and survival status and, this being the case on the occurrence of a second tumor, were compl eted for all patients by the responsible pediatrician regularly during and after cessation of therapy and sent to the Central Office. Blood and bone marrow slides for central examin ation were also sent to the Central Office.
EFS was defined as the time from diagnosis to relapse, death in remission, or the occurrence of a seco nd tumor. The EFS curve was calculated according to the Kaplan-Meier method (10) . Relapse was defined as 2::20-25% blasts in the bone marrow and/or blast cells in the periph eral blood and/or CNS involvement and/or leukemic infiltration elsewhere. Bone marrowand/or CNS relapses as well as second hematologic malignancies had to be confirmed by the DCLSG laboratory.
Late side effects. Data on late side effects were retrospectively collected in 1989-1990 by a questionnaire to be completed by the responsible pediatrician. This questionn aire contained items concerning organ dysfunction (heart, liver, lungs, CNS, skin, gastrointestinal tract, eyes, musculoskeletal system), severe or chronic diseases (hypertension, endocrine disorders, chronic infections), height, weight, pubertal development and fertility, school performance (the highest level thus far achieved), psychosocial status, employment, and insurances. No specific psychometric tests were performed. As far as possible population-based normal data and figures were used for comp arison (11, 12) .
RESULTS
Patients
Three hundred and ninety-two ex-patients were eligible for the study and available for calculation of EFS. The questionnaire on late side effects was comp leted for 273 (70%) expatients. Patient characteristics are summarized in Table 1 .
Late Events
Late events were evaluated as of January 1, 1994 . The EFS of the 392 children in longstanding CCR is 92% (SE ± 2%) at 15 y after diagnosis (Fig. 1) . Eight patients relapsed, in nine patients second malignancies occurr ed, and three patients died in CCR ( Table 2 ). The estimated cumulative proportion of late relapses and second malignancies 15 y after diagnosis is 3.2 and 3.6%, respectively.
In 5 children the second malignancy developed in the area irradiated for CNS prop hylaxis. One of the patients had also been treated with cyclophosphamide. The secondary AML and MDS occurred after treatment with doxorubicin and were associated with abnormalities of chromosome 11.
Three ex-patients died in CCR: one patien t died of preex istent hepatitis which progressed to liver cirrhosis, one patient died after 6 y of coma caused by a cerebral abscess as a consequence of otitis media during cytostatic treatment, and one patient died in a traffic accident. In four patients a histologically benign tumor was diagnosed (Table 2) . Pubertal development; progeny. Pubertal development started in due time in boys and girls, but progression was slower than in the average Dutch population in ex-patients known to be in the range of development P (pubic hair), G (genital developm ent), or M (breast development) 2-5 ( Table  3 ). The median age of the menarche in ex-patients, 12 y (range 10-14 y), was younger than in the average Dutch population: 13 y (range 11-14 y) (11) .
Tabl e 1. Patients ' characteristics
Nine infants were born: eight to female ex-patients , and one male ex-patient fathered a child. All babies were well and healthy.
Organ toxicity. Organ toxicity was most frequently reported for the eNS and the skin (Table 4) . Late cardiovasc ular, pulmonary, urogenital, gastroint estinal, hepatic, and musculoskeletal toxicity was rarely reported . The overall immunity, as measured by the incidence of severe infections, seems to be normal in leukemia patients off therapy.
Psychosocial development. A considerable part of the expatients (51%) had experienced learning problems. In the Late Side Effects
Growth. For each patient the height SDS was calculated , defined as the patients' height minus the mean for the pertaining age and sex, divided by the SD for that age. At diagnosis the mean height SDS of the patients was normal. However,~4 y after treatment the mean height SDS of both boys and girls was 1 SD lower than for the Dutch populatio n.
The height of the ex-patien ts was within the normal range of the Dutch population; however, height and weight curves showed a considerable number of ex-patients who were overweight (Fig. 2, A and B) . Both for male and female ex-patients [1972] [1973] [1974] [1975] [1976] [1977] [1978] [1979] [1980] [1981] [1982] sis, reported by the Children 's Cancer Study Group, representing a 7-fold excess of all cancers. In the Children's Cancer Study Group study, 24 (56%) out of 43 second malignancies occurred in the CNS, all in children who had been treated with cranial irradiation; however, no basocellular carcinomas were mentioned (13) . Therapy-related MDS and acute myeloid leukemia have been described in children in relation to previous treatment for solid tumors or acute lymphoblastic leukemi a with drugs reacting either directly at DNA, such as the alkylating agents, or indirectly by targeting at DNA-topoisomerase II, such as the epipodophyllotox ins, anth racyclin es, and actinomycin D. These second malignancies were associated with characteristic abnormalities of chromosomes 5 and/or 7 after alkylating agents, and of chromosome l 1q23 after DNA topoisomer ase II targeting drugs (14) (15) (16) . In this survey two cases of secondary MDS and ANNL were identified. Both patients had been treated with doxorubicin .
The data collected by the questionn aire do not suggest an increase in the incidence of cardiovasc ular, pulmonar y, urogenital, or gastrointestin al tract diseases, or an increased vulnerability of the musculosk eletal system. The overall immunity, as measured by the incidenc e of severe infection s, is normal in ex-patients. No diabetes mellitus has been observe d. (10) (11) (12) (13) (14) questionnaire the highest level of education thus far achieved had to be reported. Although many ex-patients were still too young to have reached their final educational level, it was apparent that a large proporti on of ex-patients (12%) was unable to follow normal elementary or secondary school and had to be referred to special schools for children with learning defects. In the average Dutch population only 4% of the children have to be referred (12) . There was a significant correlation between CNS irradiation at younger age and the occurrence of school problems (~p = 0.002). Fifty-five ex-patients had terminated their education and training, 27 of these had a full-time job, 13 a parttime job, and 5 were unemployed . Five ex-patients were housewives with children. Of five ex-patients the occupational status was not reported.
Medical examinations and insurances. Twenty-nine (52%) out of 55 medically examined ex-patients were rejected as unfit; 26 men for entry into military service, one woman for nurses training because of short stature, and two ex-patient for reasons unknown.
Five (3%) out of 171 ex-patients who applied for an insurance, were refused: two for health insurance, two for funeral insurance, and one for an unspecified insurance.
DISCUSSION
In this study 20 of 392 acute leukemia patients, considered to be cured, suffered from a life-threatening event. The rate of late relapses in this nationwide, multi-institutional study is slightly higher than observed in the single institution studies of St. Jude Children's Research Hospital in the same era (2) . The rate of second malign ancies is in the same range as the estimated cumulative proportion of 2.53%, 15 Y after diagno- Organ toxicity was most outspoken in the CNS. Although effective in preventing CNS relapse , it has become increasingly clear that cranial irradiati on may cause neurotoxicity leading to severe learning disabiliti es (17) . This was also observ ed in this study, as wel1 as the fact that younger age at cranial irradi ation is associ ated with more school and learning defects (18) . These school problems are largely caused by verbal and attention deficits (19, 20) . A recent study has shown an on-going decline in ful1-scale intel1igence quotient after 18 -24 Gy irradiation with the length of time from diagnosis (21).
Short stature in ex-leukemia patients may be caused by a combinati on of factor s, such as growth hormone deficiency and the development of precocious pube rty after cranial irradiation, and the longstanding administration of corticosteroids (22, 23) . In a recent study, disprop ortionate short stature was established suggesting also a direct effect of chemotherapy on the spinal cartilage growth plates (24) .
The occurrence of obesity in a high number of patients is still unexplained. Partial growth hormone deficiency by cranial irradiation, little exercise, high caloric intake , metabolic changes by long-term corticosteroid administration, or a change in body comp osition (25) may all be factors that playa role, but this phenom enon still needs further investigation.
Cranial irradiation has been related to precocious puberty. However, in our study, the median ages of the consecutive pubertal stages were higher than for the average Dutch population, indicating a delay in pubertal development, notwithstanding early menarch e in some girls. This may be associated with gonadal toxicity of the administered chemotherapy (26) . In a British study, testicul ar function after treatment for ALL , includin g cranial irradiation, was assessed by wedge biopsy at cessation of therap y and subsequently by clinical and biochemical examination, and if possible semen analysis, 10 y later. At cessation of therapy moderate to severe testicular damage was found in the majority of the boys; 10 y later testicular function had recovered completely in al1 but half of a smal1 numb er of patients with severe dam age at cessatio n of therapy, indicating that in general the outlook for male fertility in ex-leukemia patients may be considered as good (27) . The same investigators assessed that the long-term outlook for ovarian function in girls, treated with chem otherapy without cyclophosphamide or spinal or abdominal irradiation, was also good for most of the patients (28) . However, these studies need further confirmation.
The offspring of the ex-patients in the current study is normal. No increase in the incidence of congenital malformations or malignancies in children from ex-leukemia patients has been reported thus far (29, 30) .
The administration of anthracyclines has been associa ted with cardiomyopath y in a dose-related fashion (cumulative dose: > 300 mg/m'') (31) . It is of interest that in this study no clinical signs of cardiom yopathy were reported in 73 ALL patients treated with daunorubicin (cumulative dose 100 mg/ m 2 ) during induction treatment in study ALL V (7). This phase III study on the effectiveness of daunorubicin also offers an unique opportunity to study any late cardiac effects of low dose anthracycline in a comp arative way. Such a study is now underway .
It has been shown that cytostatic treatment is associated with an increase in melano cytic nevi (moles), a strong risk factor for melanoma, in long term cancer survivors (32) . However, thus far no increase in the incidence of melanoma in long term cancer survivors has been reported (33) .
Shortening of dental roots has been observed after the administration of combination chemotherapy to young children (34) . Preliminary study results suggest a relation with certain cytostatic drugs, rather than age at diagnosis for the development of these abnormalities (35) .
This survey confirms the data in the literature that prophylactic cranial irradiation is a very important factor for the long-term impairment of the quality of life of children successful1y treated for leukemia (17) (18) (19) (20) (21) . In The Netherlands, since 1984, prophylactic cranial irradiation has effectively been substituted by intensive systemic and intrathecal chemotherapy. Furthermore, it was shown in the ALL VI study that excellent results can be achieved in 70% of ALL patients without the administration of alkylating agents or anthracyclins (36) .
This survey also confirms that the majority of leukemi a patients in CCR 4 Y after cessati on of therap y has been cured ; with current more effective treatm ent strategies the final cure rate may still furth er improv e. Children cured of leukemia should have the same opportunities for education, employment , and insurances as their contemporaries who never had leukemia.
It is wrong to consider cured individuals as patients still suffering with the disease and to reject them for this reason to enter the uniform ed services. Job and insuranc e discrimination in leukemia survivors should be prohibited by law, as for example has been realized in the United States by the passage of the American s With Disabiliti es Act (37) .
However, because many of the long-term effects of treatment are still unknown, the import ance of long-t erm fol1ow-up of survivors of leukemia has to be stressed. The recommendations of the American Cancer Society Workshop on Adolescents and Young Adult s with Cancer (38 -41) could be adapted to national or local circumstances.
